Granules India’s arm gets VAI classification from USFDA for USA Facility

03 Apr 2024 Evaluate

Granules India’s wholly-owned foreign subsidiary -- Granules Pharmaceuticals’, Inc. (GPI) USA facility inspection classified as ‘Voluntary Action Indicated’ (VAI) by USFDA. The VAI inspection classification indicates that the U.S. Food and Drug Administration (USFDA) will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

Earlier, the USFDA had issued Form 483 with 5 observations post inspection on December 16, 2023, which has been now classified as VAI.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

420.20 -4.10 (-0.97%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.